Login to Your Account

AVEO Getting $10M Cash Up Front

OSI, AVEO Targeting EMT In Cancer Research Collaboration

By Jennifer Boggs

Wednesday, October 3, 2007
OSI Pharmaceuticals Inc. is joining forces with AVEO Pharmaceuticals Inc. to advance a cancer drug platform targeting epithelial-to-mesenchymal transition (EMT), a marker believed to be associated with tumor development and progression. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription